Literature DB >> 11914737

Concentrations of proinsulin like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly Study.

J S Yudkin1, M May, P Elwood, J W G Yarnell, R Greenwood, G Davey Smith.   

Abstract

AIMS/HYPOTHESIS: Higher concentrations of insulin correlate with several coronary heart disease (CHD) risk factors and have been shown to predict incident CHD in several studies, leading to hypotheses concerning the proatherogenic properties of insulin. However, in cross-sectional studies, relationships of concentrations of the insulin precursor molecules, proinsulin and des 31, 32 proinsulin, relate as strongly, or more strongly, to levels of risk factors and to (prevalent) CHD.
METHODS: We investigated the relationship between concentrations of insulin, measured with a specific assay, and of proinsulin-like molecules, and risk factors in 1181 non-diabetic men 50-64 years old during Phase II of the Caerphilly Study. We also related concentrations of these molecules to incident CHD during the 10-14 years follow-up.
RESULTS: The relationship between concentrations of insulin, of proinsulin and of des 31, 32 proinsulin and BMI ( r = 0.36-0.45), triglyceride (r = 0.25-0.31), high density lipoprotein- (HDL-) cholesterol (r = -0.17 to -0.21), systolic ( r = 0.05-0.11) and diastolic blood pressure ( r = 0.11-0.15) were similarly close, those with risk factors being somewhat and similarly reduced after adjustment for BMI. The correlation between insulin and of proinsulin-like molecules and those plasminogen activator inhibitor-1 (PAI-1) antigen was also similar (r = 0.28-0.29). There was a negative correlation between concentrations of proinsulin-like molecules - but not insulin - and birth weight. Insulin concentrations correlated positively with height ( r = 0.12). In logistic regression models, concentrations of proinsulin-like molecules, but not insulin, predicted incident of CHD over a follow-up of 10-14 years (insulin - standardised odds ratio (SOR) 1.30 (95 %-CI) 0.91, 1.85), p = 0.15; des 31, 32 proinsulin - SOR 1.38 (95 %-CI 1.02, 1.85), p = 0.034; sum of proinsulin-like molecules - SOR 1.54 (95 %-CI 1.07, 2.20), p = 0.019 after adjusting for age and BMI. The predictive ability of these molecules was reduced by around one third after adjustment for standard risk factors and concentrations of tryglyceride and HDL-cholesterol, and by about half after further adjustment for PAI-1 concentrations. CONCLUSION/
INTERPRETATION: We conclude that concentrations of proinsulin-like molecules provide a better way to predict the incidence of CHD than those of insulin. However, the lack of biological evidence for a causative relationship suggests an association through a common antecedent, and this antecedent is not likely to be intrauterine growth retardation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11914737     DOI: 10.1007/s00125-001-0756-7

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  20 in total

1.  Insulin sensitivity, proinsulin and insulin as predictors of coronary heart disease. A population-based 10-year, follow-up study in 70-year old men using the euglycaemic insulin clamp.

Authors:  B Zethelius; H Lithell; C N Hales; C Berne
Journal:  Diabetologia       Date:  2005-04-01       Impact factor: 10.122

2.  Clinical and Laboratory Evaluation of a New Specific Point-of-Care Test for Intact Proinsulin.

Authors:  Andreas Pfützner; Anke H Pfützner; Peter H Kann; Gunther Burgard
Journal:  J Diabetes Sci Technol       Date:  2016-09-25

Review 3.  Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone.

Authors:  Andreas Pfützner; Thomas Forst
Journal:  J Diabetes Sci Technol       Date:  2011-05-01

4.  Bileopancreatic diversion with duodenal switch lowers both early and late phases of glucose, insulin and proinsulin responses after meal.

Authors:  Hans-Erik Johansson; Arvo Haenni; F Anders Karlsson; Britt Edén-Engström; Margareta Ohrvall; Magnus Sundbom; Björn Zethelius
Journal:  Obes Surg       Date:  2010-05       Impact factor: 4.129

5.  Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies.

Authors: 
Journal:  Diabetologia       Date:  2004-07-07       Impact factor: 10.122

6.  Molecular scanning of the human carboxypeptidase E gene for mutations in Chinese subjects with coronary atherosclerosis.

Authors:  En-Zhi Jia; Jie Wang; Zhi-Jian Yang; Tie-Bing Zhu; Lian-Sheng Wang; Bo Chen; Ke-Jiang Cao; Jun Huang; Wen-Zhu Ma
Journal:  Mol Cell Biochem       Date:  2007-10-24       Impact factor: 3.396

7.  Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes.

Authors:  T Forst; M Larbig; C Hohberg; S Forst; S Diessel; M Borchert; W Roth; A Pfützner
Journal:  Diabetes Obes Metab       Date:  2010-05       Impact factor: 6.577

8.  Risk factors for type 2 diabetes mellitus preceded by β-cell dysfunction, insulin resistance, or both in older adults: the Cardiovascular Health Study.

Authors:  Fumiaki Imamura; Kenneth J Mukamal; James B Meigs; José A Luchsinger; Joachim H Ix; David S Siscovick; Dariush Mozaffarian
Journal:  Am J Epidemiol       Date:  2013-05-24       Impact factor: 4.897

9.  Alterations in proinsulin and insulin dynamics, HDL Cholesterol and ALT after gastric bypass surgery. A 42-months follow-up study.

Authors:  Hans-Erik Johansson; Arvo Haenni; Margareta Ohrvall; Magnus Sundbom; Björn Zethelius
Journal:  Obes Surg       Date:  2009-02-20       Impact factor: 4.129

10.  Proinsulin:insulin and insulin:glucose ratios as predictors of carotid plaque growth: a population-based 7 year follow-up of the Tromsø Study.

Authors:  J Kronborg; S H Johnsen; I Njølstad; I Toft; B O Eriksen; T Jenssen
Journal:  Diabetologia       Date:  2007-06-09       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.